Aurélia Henn1,2, Clara Flateau1, Sébastien Gallien3,4. 1. Service d'immunologie clinique et maladies infectieuses, CHU Henri Mondor, APHP, 51 Avenue du Maréchal de Lattre de Tassigny, 94010, Creteil, France. 2. Faculté de médecine, Université Paris-Est Créteil, Créteil, France. 3. Service d'immunologie clinique et maladies infectieuses, CHU Henri Mondor, APHP, 51 Avenue du Maréchal de Lattre de Tassigny, 94010, Creteil, France. sebastien.gallien@aphp.fr. 4. Faculté de médecine, Université Paris-Est Créteil, Créteil, France. sebastien.gallien@aphp.fr.
Abstract
PURPOSE OF REVIEW: The purpose of this review was to provide current data on clinical presentation, diagnosis, and treatment of primary HIV infection (PHI). RECENT FINDINGS: In 65 to 95% of cases, PHI causes acute retroviral syndrome presenting with unspecific flu-like symptoms. Symptomatic PHI was associated with a faster clinical and immunological progression of HIV infection. Point-of-care tests remain less sensitive than fourth-generation immunoassays (IA) in PHI, especially after tenofovir-based prophylaxis use. Early antiretroviral treatment (ART) started during PHI prevents HIV transmission and decreases viral and immunological reservoir constitution. Recommended ART regimens in PHI are combinations of tenofovir and emtricitabine with either darunavir/ritonavir, or dolutegravir. Starting ART the earliest is highly recommended for clinical, virological, immunological, and public health benefits. Reducing HIV reservoir constitution in PHI may optimize potential opportunities for future functional cure.
PURPOSE OF REVIEW: The purpose of this review was to provide current data on clinical presentation, diagnosis, and treatment of primary HIV infection (PHI). RECENT FINDINGS: In 65 to 95% of cases, PHI causes acute retroviral syndrome presenting with unspecific flu-like symptoms. Symptomatic PHI was associated with a faster clinical and immunological progression of HIV infection. Point-of-care tests remain less sensitive than fourth-generation immunoassays (IA) in PHI, especially after tenofovir-based prophylaxis use. Early antiretroviral treatment (ART) started during PHI prevents HIV transmission and decreases viral and immunological reservoir constitution. Recommended ART regimens in PHI are combinations of tenofovir and emtricitabine with either darunavir/ritonavir, or dolutegravir. Starting ART the earliest is highly recommended for clinical, virological, immunological, and public health benefits. Reducing HIV reservoir constitution in PHI may optimize potential opportunities for future functional cure.
Entities:
Keywords:
Acute retroviral syndrome; Antiretroviral treatment; Fiebig stages; HIV diagnosis; Point-of-care tests; Primary HIV infection
Authors: Dominique L Braun; Roger D Kouyos; Belinda Balmer; Christina Grube; Rainer Weber; Huldrych F Günthard Journal: Clin Infect Dis Date: 2015-05-19 Impact factor: 9.079
Authors: Joanne D Stekler; Joshua D O'Neal; Aric Lane; Fred Swanson; Janine Maenza; Claire E Stevens; Robert W Coombs; Joan A Dragavon; Paul D Swenson; Matthew R Golden; Bernard M Branson Journal: J Clin Virol Date: 2013-12 Impact factor: 3.168
Authors: Christopher D Pilcher; George Joaki; Irving F Hoffman; Francis E A Martinson; Clement Mapanje; Paul W Stewart; Kimberly A Powers; Shannon Galvin; David Chilongozi; Syze Gama; Matthew A Price; Susan A Fiscus; Myron S Cohen Journal: AIDS Date: 2007-08-20 Impact factor: 4.177
Authors: Marlous L Grijsen; Radjin Steingrover; Ferdinand W N M Wit; Suzanne Jurriaans; Annelies Verbon; Kees Brinkman; Marchina E van der Ende; Robin Soetekouw; Frank de Wolf; Joep M A Lange; Hanneke Schuitemaker; Jan M Prins Journal: PLoS Med Date: 2012-03-27 Impact factor: 11.069
Authors: Lewis H Kuller; Russell Tracy; Waldo Belloso; Stephane De Wit; Fraser Drummond; H Clifford Lane; Bruno Ledergerber; Jens Lundgren; Jacqueline Neuhaus; Daniel Nixon; Nicholas I Paton; James D Neaton Journal: PLoS Med Date: 2008-10-21 Impact factor: 11.069